<DOC>
	<DOC>NCT01554917</DOC>
	<brief_summary>This study is intended to evaluate the safety and efficacy of Iguratimod in patients with active Rheumatoid Arthritis.</brief_summary>
	<brief_title>A Study of Iguratimod in Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>This is a multi-center, open, single arm study.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Subjects with a diagnosis of RA Subjects who have active RA at the time of screening Subjects who haven't used any antirheumatic drugs or have used antirheumatic drugs for more than 3 months at the time of screening Written informed consent Subjects with serious cardiovascular, renal, hematologic or endocrine diseases Pregnant or lactating women ALT&gt;1.5×ULN, AST&gt;1.5×ULN, Cr&gt;135umol/L WBC&lt;4×109/L，HGB&lt;85g/L，PLT&lt;100×109/L Subjects with uncontrolled infection Patients with active gastrointestinal diseases (such as gastric ulcer, etc.) Allergic to any of the study drugs History of alcoholism Subjects receiving live vaccines within 3 months prior to study entry Subjects participating in other clinical study within 3 months prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Iguratimod</keyword>
</DOC>